STAT Plus Latest Alnylam data underscores positive results for new RNAi drug candidate at least for some patients

STAT Plus: Latest Alnylam data underscores positive results for new RNAi drug candidate, at least for some patients

Alnylam on Friday released a full analysis of its clinical trial data for its drug candidate givosiran, which relies on a Nobel prize-winning gene-silencing technique.

More From BioPortfolio on "STAT Plus: Latest Alnylam data underscores positive results for new RNAi drug candidate, at least for some patients"